A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
A new immunosuppressive drug, based on the inhibition of important enzymes in the immune
system, called JAK, is being developed by Pfizer to prevent transplant rejection. Since many
treatments for transplant rejection may be administered together, this research study will
analyze the effects of common transplant rejection therapies, Tacrolimus and Cyclosporine, on
the JAK inhibitor, CP-690,550.